Fate Therapeutics Reports Q4 & FY25 Financial Results, Expands CAR T-cell Therapy Enrollment

• Fate Therapeutics reports Q4 and FY25 financial results • FT819-102 autoimmune basket protocol enables outpatient treatment • 15 patients enrolled in FT819 Phase 1 trial • 4 systemic sclerosis patients and 1 idiopathic inflammatory myopathy patient treated • 1 systemic sclerosis patient shows meaningful disease improvement • 1 colorectal cancer patient shows 50% reduction in CEA levels